Donepezil-Hcl 1 A Pharma

Donepezil-HCl 1 A Pharma is an oral medication containing the active ingredient donepezil hydrochloride, supplied as a generic formulation without a specific brand name. It belongs to the acetylcholinesterase inhibitor class and is marketed in the European Union for prescription use. The product is intended for patients diagnosed with mild to moderate Alzheimer’s disease, aiming to support cognitive function through its pharmacologic action.

Donepezil-HCl 1 A Pharma is prescribed primarily for the symptomatic treatment of Alzheimer’s disease in its mild to moderate stages. Clinical use focuses on improving cognition, memory, and daily functioning in affected individuals.

- Management of mild to moderate Alzheimer’s disease symptoms - Adjunct therapy to support cognitive performance - Use in patients with documented cholinergic deficits - Consideration for patients who have not responded to non‑pharmacologic interventions - Integration into a comprehensive dementia care plan

Side effects of donepezil may vary in frequency and severity. Patients should be aware of both common and less frequent serious reactions.

Common: - Nausea or upset stomach - Diarrhea or loose stools - Insomnia or vivid dreams - Muscle cramps or fatigue - Headache - Dizziness

Serious: - Bradycardia or heart block - Severe gastrointestinal bleeding - Hepatotoxicity with elevated liver enzymes - Seizures or convulsions - Allergic reactions such as rash or angioedema - Persistent vomiting leading to dehydration

Before initiating Donepezil-HCl 1 A Pharma, clinicians should evaluate patient history and monitor for potential risks.

- Assess cardiac function, especially in patients with arrhythmias - Review liver function tests prior to treatment - Caution in patients with a history of peptic ulcer disease or gastrointestinal bleeding - Monitor for signs of severe weight loss or malnutrition - Evaluate for concurrent use of other cholinergic agents - Discuss pregnancy and lactation status, as safety data are limited

Donepezil can interact with several medications, requiring careful review of a patient’s medication list.

Avoid: - Anticholinergic drugs such as atropine or scopolamine - Non‑selective beta‑blockers that may exacerbate bradycardia - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) - Drugs that prolong the QT interval

Use with caution: - Other acetylcholinesterase inhibitors - NSAIDs or aspirin in patients at risk for GI bleeding - Antidepressants that affect serotonin levels - Medications affecting hepatic metabolism (e.g., rifampin)